The Global Next Generation Sequencing Market in terms of revenue was estimated to be worth $13 billion in 2022 and is poised to reach $27 billion by 2030, growing at a CAGR of 15.7% from 2022 to 2030.

The increasing demand for personalized medicine, rising prevalence of cancer and genetic disorders, and decreasing costs of sequencing are some of the key factors driving the growth of the market. The global next generation sequencing (NGS) market refers to the market for technologies and services used to perform high-throughput DNA sequencing. NGS technologies have revolutionized genomics research and are being used in a wide range of applications including clinical diagnosis, drug discovery, and agriculture.

The market is segmented based on product & service, technology, application, end use, and region. Based on product & service, the market is divided into consumables, platforms, and services. The consumables segment is expected to account for the largest share of the market due to the high usage of reagents, kits, and other consumables in NGS workflows.

Based on technology, the market is segmented into sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, and others. SBS is expected to be the largest segment due to its high accuracy and throughput.

Based on application, the market is segmented into oncology, reproductive health, clinical diagnosis, drug discovery, and others. The oncology segment is expected to be the largest due to the increasing use of NGS in cancer diagnosis and treatment.

Based on end use, the market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, hospitals & clinics, and others. The academic & research institutes segment is expected to be the largest due to the high usage of NGS in basic and translational research.

Geographically, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to be the largest market due to the presence of a large number of NGS companies and research institutions in the region. Asia Pacific is expected to be the fastest-growing market due to increasing investments in genomics research and rising awareness about personalized medicine.

Some of the key players in the global NGS market include Illumina, Inc., Thermo Fisher Scientific, Inc., Pacific Biosciences of California, Inc., BGI Group, Agilent Technologies, Inc., and Oxford Nanopore Technologies, Inc.

Market Dynamics

Driving Factors

There are several driving factors behind the growth of the global next generation sequencing (NGS) market:

Increased funding for genomics research: The availability of funding from government and private organizations for genomics research is driving the development of new NGS-based applications and technologies.

Technological advancements in bioinformatics: The development of advanced bioinformatics tools and software for data analysis and interpretation is improving the accuracy and efficiency of NGS-based research and clinical applications.

Growing awareness and adoption of precision medicine: The growing awareness and adoption of precision medicine, which involves using a patient's genetic information to develop personalized treatment plans, is driving the demand for NGS-based diagnostic and treatment solutions.

Restraining Factors

There are also several restraining factors that may limit the growth of the global next generation sequencing (NGS) market:

Competition from other technologies: NGS faces competition from other genomic technologies such as microarrays, PCR, and Sanger sequencing, which may limit its adoption in some applications.

Limited availability of skilled personnel: The implementation and operation of NGS workflows requires skilled personnel with expertise in genomics, bioinformatics, and data analysis, which may limit the adoption of NGS by some organizations.

Complexity of data analysis: The analysis and interpretation of NGS data can be complex and require advanced bioinformatics skills, which may limit the adoption of NGS by some researchers and clinicians who lack these skills.

Challenges Factors

The global next generation sequencing (NGS) market faces several challenges that may limit its growth and adoption:

Ethical and regulatory issues: The use of NGS in clinical practice raises ethical and regulatory issues related to data privacy, informed consent, and the interpretation and reporting of genetic results. The development of ethical and regulatory frameworks is needed to ensure the responsible and ethical use of NGS.

Limited availability of skilled personnel: The implementation and operation of NGS workflows requires skilled personnel with expertise in genomics, bioinformatics, and data analysis. The development of training programs and educational resources is needed to address the shortage of skilled personnel.

Cost: The cost of NGS equipment and services remains relatively high, which may limit adoption by some researchers and clinicians. The development of cost-effective solutions and technologies is needed to make NGS more accessible to a wider range of organizations and applications.

Opportunity Factors

The global next generation sequencing (NGS) market presents several opportunities for growth and innovation:

Advancements in technology: The development of new sequencing technologies and platforms with higher accuracy, speed, and throughput presents an opportunity for the improvement of NGS-based research and clinical applications. The development of new bioinformatics tools and workflows is also important for the simplification and automation of data analysis.

Personalized medicine: The growing demand for personalized medicine presents an opportunity for the adoption of NGS-based diagnostic and treatment solutions. The development of new applications and solutions that can enhance the accuracy and efficiency of personalized medicine presents an opportunity for growth and innovation.

Government initiatives: The availability of funding and government initiatives for genomics research and healthcare presents an opportunity for growth and market penetration. The development of partnerships and collaborations with government agencies and institutions can help to drive innovation and growth in the NGS market.

Segmentation Analysis

Technology Outlook

Sequencing by synthesis is the most commonly used technology in the NGS market, driven by its high accuracy, throughput, and affordability. It is widely used in research and clinical applications, including oncology, infectious diseases, and personalized medicine.

Ion semiconductor sequencing is another popular technology in the NGS market, driven by its high speed, simplicity, and affordability. It is commonly used in applications such as targeted sequencing, whole genome sequencing, and gene expression analysis.

Single-molecule real-time sequencing is a newer technology in the NGS market, driven by its ability to provide long-read sequencing data with high accuracy and throughput. It is commonly used in applications such as genome assembly, haplotype phasing, and epigenetic analysis. The "others" category includes emerging sequencing technologies such as nanopore sequencing, hybridization-based sequencing, and synthetic long-read sequencing. These technologies present significant opportunities for growth and innovation in the NGS market, driven by their ability to provide long-read sequencing data with high accuracy and throughput.

Product Outlook

Consumables are the largest product segment in the NGS market, driven by the increasing demand for reagents, kits, and other consumables in NGS-based research and clinical applications. The consumables segment is further sub-segmented into sample preparation consumables, library preparation and target enrichment kits, sequencing consumables, and data analysis software.

Platforms are the second-largest product segment in the NGS market, driven by the increasing adoption of NGS platforms in research and clinical applications. The platforms segment is further sub-segmented into benchtop sequencers, standalone sequencers, and cloud-based sequencers.

Services are the fastest-growing product segment in the NGS market, driven by the increasing demand for NGS-based services such as sequencing, data analysis, and bioinformatics. The services segment is further sub-segmented into sequencing services, data analysis services, and other services such as consulting and training.

The consumables segment is expected to continue to dominate the NGS market, driven by the increasing demand for reagents, kits, and other consumables in NGS-based research and clinical applications. The platforms segment is also expected to grow, driven by the increasing adoption of NGS platforms in research and clinical applications. The services segment presents significant opportunities for growth, driven by the increasing demand for NGS-based services such as sequencing, data analysis, and bioinformatics.

Regional Analysis

North America is the largest market for NGS, driven by the presence of a large number of research institutions, healthcare providers, and biotechnology companies. The United States is the largest market in the region, accounting for a significant share of the global market.

Europe is the second-largest market for NGS, driven by the increasing adoption of NGS in research and clinical applications. The United Kingdom, Germany, and France are the largest markets in the region, accounting for a significant share of the global market.

The Asia-Pacific region presents significant opportunities for growth and market penetration, driven by the increasing demand for genomics research and personalized medicine. China, Japan, and India are the largest markets in the region, accounting for a significant share of the global market.

Latin America presents significant opportunities for growth and market penetration, driven by the increasing adoption of NGS in research and clinical applications. Brazil, Mexico, and Argentina are the largest markets in the region, accounting for a significant share of the global market.

The Middle East and Africa present significant opportunities for growth and market penetration, driven by the increasing demand for genomics research and personalized medicine. Saudi Arabia, South Africa, and the United Arab Emirates are the largest markets in the region, accounting for a significant share of the global market.

Scope Of Report:

The Global Next Generation Sequencing Market has been segmented into:
By Technology

• WGS
• Whole Exome Sequencing

Targeted Sequencing & Resequencing

• DNA-based
• RNA-based

By Product

• Platforms
• Sequencing
• Data Analysis
• Consumables
• Sample preparation
• Target Enrichment
• Others

By Application

• Oncology
• Diagnostics and Screening
• Oncology Screening
• Sporadic Cancer
• Inherited Cancer
• Companion Diagnostics
• Other Diagnostics

Research Studies

• Clinical Investigation
• Infectious Diseases
• Inherited Diseases
• Idiopathic Diseases
• Non-communicable/Other Diseases

Reproductive Health

• NIPT
• Aneuploidy
• Microdeletions
• PGT
• Newborn Genetic Screening
• Single Gene Analysis
• HLA Typing/Immune System Monitoring
• Metagenomics, Epidemiology & Drug Development
• Agrigenomics & Forensics
• Consumer Genomics

By Workflow

Pre-sequencing

• NGS Library Preparation Kits
• Semi-automated Library Preparation
• Automated Library Preparation
• Clonal Amplification

Sequencing

• NGS Data Analysis
• NGS Primary Data Analysis
• NGS Secondary Data Analysis
• NGS Tertiary Data Analysis

By Region

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
  • Germany
  • France
  • Italy
  • Spain
  • UK
  • Nordic Countries
    • Denmark
    • Finland
    • Iceland
    • Sweden
    • Norway
  • Benelux Union
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
• Rest of Asia-Pacific
• The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America

Market Players 

The global next generation sequencing is highly competitive and fragmented, with numerous players vying for market share. Some of the key companies in the market are:

• Illumina
• F. Hoffman-La Roche Ltd.
• QIAGEN
• Thermo Fisher Scientific, Inc.
• Bio-Rad Laboratories, Inc.
• Oxford Nanopore Technologies
• PierianDx
• Genomatix GmbH
• DNASTAR, Inc.
• Perkin Elmer, Inc.
• Eurofins GATC Biotech GmbH
• BGI

Illumina is a leading player in the NGS market, offering a wide range of sequencing platforms, consumables, and services for research and clinical applications. The company has a dominant market share in the NGS market, driven by its established track record of accuracy, throughput, and affordability.

Thermo Fisher Scientific is another major player in the NGS market, offering a comprehensive portfolio of sequencing platforms, consumables, and services for research and clinical applications. The company has a strong market presence in the NGS market, driven by its focus on innovation and customer-centric approach.

BGI Group is a leading player in the NGS market, offering a range of sequencing platforms, consumables, and services for research and clinical applications. The company has a significant market share in the NGS market, driven by its expertise in genomics research and its focus on emerging markets such as Asia-Pacific and Latin America.

Pacific Biosciences is a major player in the NGS market, offering a range of sequencing platforms and services for research and clinical applications. The company has a unique niche in the NGS market, driven by its focus on long-read sequencing and its ability to provide high-quality sequencing data for complex genomes.

Oxford Nanopore Technologies is a growing player in the NGS market, offering a range of nanopore sequencing platforms and services for research and clinical applications. The company has a unique niche in the NGS market, driven by its focus on long-read sequencing and its ability to provide real-time sequencing data.

Strategic Developments

In 2020, Illumina Inc. announced its intention to acquire Grail Inc., a cancer detection startup, for $8 billion. The acquisition would strengthen Illumina's position in the NGS market by adding Grail's innovative cancer detection technology to its portfolio.

In 2020, BGI Genomics Co. Ltd., a subsidiary of BGI Group, raised $207 million in a public offering on the Shenzhen Stock Exchange. The funds raised would be used to expand the company's NGS sequencing capacity and develop new applications for its sequencing technology.

In 2019, Qiagen N.V. acquired N-of-One, Inc., a provider of molecular decision support solutions, for $248 million. The acquisition would strengthen Qiagen's portfolio of bioinformatics solutions for NGS data analysis.

In 2019, Pacific Biosciences of California, Inc. raised $100 million in a public offering of common stock. The funds raised would be used to support the development and commercialization of the company's long-read sequencing technology.

In 2018, Illumina Inc. acquired Edico Genome, a provider of data analysis solutions for NGS, for $100 million. The acquisition would enable Illumina to integrate Edico's data analysis technology into its sequencing platforms, improving the speed and accuracy of NGS data analysis.